Toll Free: 1-888-928-9744

Malaria - Pipeline Review, H1 2016

Published: May 18, 2016 | Pages: 423 | Publisher: Global Markets Direct | Industry: Pharmaceuticals & Healthcare | Report Format: Electronic (PDF)

Malaria - Pipeline Review, H1 2016

Summary

Global Markets Direct's, 'Malaria - Pipeline Review, H1 2016', provides an overview of the Malaria pipeline landscape. 

The report provides comprehensive information on the therapeutics under development for Malaria, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Malaria and features dormant and discontinued projects. 

Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data.

Scope

- The report provides a snapshot of the global therapeutic landscape of Malaria
- The report reviews pipeline therapeutics for Malaria by companies and universities/research institutes based on information derived from company and industry-specific sources 
- The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages 
- The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities 
- The report reviews key players involved Malaria therapeutics and enlists all their major and minor projects
- The report assesses Malaria therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type 
- The report summarizes all the dormant and discontinued pipeline projects 
- The report reviews latest news related to pipeline therapeutics for Malaria

Reasons To Buy

- Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage 
- Identify and understand important and diverse types of therapeutics under development for Malaria
- Identify potential new clients or partners in the target demographic
- Develop strategic initiatives by understanding the focus areas of leading companies 
- Plan mergers and acquisitions effectively by identifying key players and it's most promising pipeline therapeutics
- Devise corrective measures for pipeline projects by understanding Malaria pipeline depth and focus of Indication therapeutics
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and Scope
- Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline
 Table of Contents
Table of Contents 2 Introduction 6 Malaria Overview 7 Therapeutics Development 8 Malaria - Therapeutics under Development by Companies 10 Malaria - Therapeutics under Investigation by Universities/Institutes 15 Malaria - Pipeline Products Glance 19 Malaria - Products under Development by Companies 23 Malaria - Products under Investigation by Universities/Institutes 30 Malaria - Companies Involved in Therapeutics Development 36 Malaria - Therapeutics Assessment 96 Drug Profiles 107 Malaria - Recent Pipeline Updates 355 Malaria - Dormant Projects 378 Malaria - Discontinued Products 389 Malaria - Product Development Milestones 391 Appendix 400
List of Tables
Number of Products under Development for Malaria, H1 2016 30 Number of Products under Development for Malaria - Comparative Analysis, H1 2016 31 Number of Products under Development by Companies, H1 2016 32 Number of Products under Development by Companies, H1 2016 (Contd..1) 33 Number of Products under Development by Companies, H1 2016 (Contd..2) 34 Number of Products under Development by Companies, H1 2016 (Contd..3) 35 Number of Products under Development by Companies, H1 2016 (Contd..4) 36 Number of Products under Investigation by Universities/Institutes, H1 2016 37 Number of Products under Investigation by Universities/Institutes, H1 2016 (Contd..1) 38 Number of Products under Investigation by Universities/Institutes, H1 2016 (Contd..2) 39 Number of Products under Investigation by Universities/Institutes, H1 2016 (Contd..3) 40 Comparative Analysis by Late Stage Development, H1 2016 41 Comparative Analysis by Clinical Stage Development, H1 2016 42 Comparative Analysis by Early Stage Development, H1 2016 43 Comparative Analysis by Unknown Stage Development, H1 2016 44 Products under Development by Companies, H1 2016 45 Products under Development by Companies, H1 2016 (Contd..1) 46 Products under Development by Companies, H1 2016 (Contd..2) 47 Products under Development by Companies, H1 2016 (Contd..3) 48 Products under Development by Companies, H1 2016 (Contd..4) 49 Products under Development by Companies, H1 2016 (Contd..5) 50 Products under Development by Companies, H1 2016 (Contd..6) 51 Products under Investigation by Universities/Institutes, H1 2016 52 Products under Investigation by Universities/Institutes, H1 2016 (Contd..1) 53 Products under Investigation by Universities/Institutes, H1 2016 (Contd..2) 54 Products under Investigation by Universities/Institutes, H1 2016 (Contd..3) 55 Products under Investigation by Universities/Institutes, H1 2016 (Contd..4) 56 Products under Investigation by Universities/Institutes, H1 2016 (Contd..5) 57 Malaria - Pipeline by 4SC AG, H1 2016 58 Malaria - Pipeline by Acetylon Pharmaceuticals, Inc., H1 2016 59 Malaria - Pipeline by Actelion Ltd, H1 2016 60 Malaria - Pipeline by Agilvax, Inc., H1 2016 61 Malaria - Pipeline by Akshaya Bio Inc., H1 2016 62 Malaria - Pipeline by Amura Holdings Limited, H1 2016 63 Malaria - Pipeline by Artificial Cell Technologies, Inc., H1 2016 64 Malaria - Pipeline by AstraZeneca Plc, H1 2016 65 Malaria - Pipeline by Bharat Biotech International Limited, H1 2016 66 Malaria - Pipeline by Callaghan Innovation Research Ltd., H1 2016 67 Malaria - Pipeline by Carna Biosciences, Inc., H1 2016 68 Malaria - Pipeline by CEL-SCI Corporation, H1 2016 69 Malaria - Pipeline by Celgene Corporation, H1 2016 70 Malaria - Pipeline by Cellceutix Corporation, H1 2016 71 Malaria - Pipeline by Chong Kun Dang Pharmaceutical Corp., H1 2016 72 Malaria - Pipeline by Cilian AG, H1 2016 73 Malaria - Pipeline by Daiichi Sankyo Company, Limited, H1 2016 74 Malaria - Pipeline by DesignMedix, Inc., H1 2016 75 Malaria - Pipeline by Eisai Co., Ltd., H1 2016 76 Malaria - Pipeline by Genocea Biosciences, Inc., H1 2016 77 Malaria - Pipeline by GenVec, Inc., H1 2016 78 Malaria - Pipeline by Genzyme Corporation, H1 2016 79 Malaria - Pipeline by GlaxoSmithKline Plc, H1 2016 80 Malaria - Pipeline by Hager Biosciences, LLC, H1 2016 81 Malaria - Pipeline by iBio, Inc., H1 2016 82 Malaria - Pipeline by Imaxio SA, H1 2016 83 Malaria - Pipeline by Immtech Pharmaceuticals, Inc., H1 2016 84 Malaria - Pipeline by Inovio Pharmaceuticals, Inc., H1 2016 85 Malaria - Pipeline by IPCA Laboratories Limited, H1 2016 86 Malaria - Pipeline by IRBM Science Park SpA, H1 2016 87 Malaria - Pipeline by Jenrin Discovery, Inc., H1 2016 88 Malaria - Pipeline by Jomaa Pharma GmbH, H1 2016 89 Malaria - Pipeline by Kancera AB, H1 2016 90 Malaria - Pipeline by Lipocure Ltd., H1 2016 91 Malaria - Pipeline by Lipotek Pty Ltd., H1 2016 92 Malaria - Pipeline by LondonPharma Ltd, H1 2016 93 Malaria - Pipeline by Merck KGaA, H1 2016 94 Malaria - Pipeline by MerLion Pharmaceuticals Pte Ltd, H1 2016 95 Malaria - Pipeline by Microbiotix, Inc., H1 2016 96 Malaria - Pipeline by Mucosis B.V., H1 2016 97 Malaria - Pipeline by Mymetics Corporation, H1 2016 98 Malaria - Pipeline by Novartis AG, H1 2016 99 Malaria - Pipeline by PaxVax, Inc., H1 2016 100 Malaria - Pipeline by Pfenex Inc., H1 2016 101 Malaria - Pipeline by Pfizer Inc., H1 2016 102 Malaria - Pipeline by Protein Potential, LLC, H1 2016 103 Malaria - Pipeline by Raptor Pharmaceutical Corp., H1 2016 104 Malaria - Pipeline by Rodos BioTarget GmbH, H1 2016 105 Malaria - Pipeline by Sanaria Inc., H1 2016 106 Malaria - Pipeline by Sanofi, H1 2016 107 Malaria - Pipeline by SATT Lutech SAS, H1 2016 108 Malaria - Pipeline by SBI Pharmaceuticals Co., Ltd., H1 2016 109 Malaria - Pipeline by SEEK Group, H1 2016 110 Malaria - Pipeline by Selecta Biosciences, Inc., H1 2016 111 Malaria - Pipeline by Sigma-Tau S.p.A., H1 2016 112 Malaria - Pipeline by Takeda Pharmaceutical Company Limited, H1 2016 113 Malaria - Pipeline by Telormedix SA, H1 2016 114 Malaria - Pipeline by Tomegavax, Inc., H1 2016 115 Malaria - Pipeline by VLP Biotech, Inc., H1 2016 116 Malaria - Pipeline by Zydus Cadila Healthcare Limited, H1 2016 117 Assessment by Monotherapy Products, H1 2016 118 Assessment by Combination Products, H1 2016 119 Number of Products by Stage and Target, H1 2016 121 Number of Products by Stage and Mechanism of Action, H1 2016 124 Number of Products by Stage and Route of Administration, H1 2016 126 Number of Products by Stage and Molecule Type, H1 2016 128 Malaria Therapeutics - Recent Pipeline Updates, H1 2016 377 Malaria - Dormant Projects, H1 2016 400 Malaria - Dormant Projects (Contd..1), H1 2016 401 Malaria - Dormant Projects (Contd..2), H1 2016 402 Malaria - Dormant Projects (Contd..3), H1 2016 403 Malaria - Dormant Projects (Contd..4), H1 2016 404 Malaria - Dormant Projects (Contd..5), H1 2016 405 Malaria - Dormant Projects (Contd..6), H1 2016 406 Malaria - Dormant Projects (Contd..7), H1 2016 407 Malaria - Dormant Projects (Contd..8), H1 2016 408 Malaria - Dormant Projects (Contd..9), H1 2016 409 Malaria - Dormant Projects (Contd..10), H1 2016 410 Malaria - Discontinued Products, H1 2016 411 Malaria - Discontinued Products (Contd..1), H1 2016 412


List of Figures
Number of Products under Development for Malaria, H1 2016 30 Number of Products under Development for Malaria - Comparative Analysis, H1 2016 31 Number of Products under Development by Companies, H1 2016 32 Number of Products under Investigation by Universities/Institutes, H1 2016 37 Comparative Analysis by Late Stage Development, H1 2016 41 Comparative Analysis by Clinical Stage Development, H1 2016 42 Comparative Analysis by Early Stage Products, H1 2016 43 Assessment by Monotherapy Products, H1 2016 118 Assessment by Combination Products, H1 2016 119 Number of Products by Top 10 Targets, H1 2016 120 Number of Products by Stage and Top 10 Targets, H1 2016 120 Number of Products by Top 10 Mechanism of Actions, H1 2016 123 Number of Products by Stage and Top 10 Mechanism of Actions, H1 2016 123 Number of Products by Routes of Administration, H1 2016 125 Number of Products by Stage and Routes of Administration, H1 2016 125 Number of Products by Top 10 Molecule Types, H1 2016 127 Number of Products by Stage and Top 10 Molecule Types, H1 2016 127

To request a free sample copy of this report, please complete the form below.

This website is secure and your personal details are safe. Privacy policy

Global automotive coatings market size is likely to be valued at USD 27.7 billion by 2022; as per a new research report by Radiant Insights, Inc. Vehicle aesthetics, UV radiation and temperature variation protection and enhance durability are certain

Read More...

Global fumaric acid market size is anticipated to be valued at USD 764.8 million by 2020, as per a new research report by Radiant Insights, Inc. Growing processed food demand coupled with RTD (ready-to-drink) beverages consumption is expected to driv

Read More...

Global thermoplastic polyurethane (TPU) films market size is likely to be valued at USD 724.6 million by 2020; as per a new research report by Radiant Insights, Inc. Increase in lightweight plastics demand in order to achieve vehicle fuel efficiency

Read More...

Global data center UPS market size is estimated to reach USD 5.7 billion by 2020, as per a new research report by Radiant Insights, Inc. Declining tolerance levels pertaining to data loss along with amplifying acceptance of cloud computing is likely

Read More...

Global 3D scanning market is expected to be valued at USD 4,900.7 million by 2020, as per a new research report by Radiant Insights, Inc. Increasing need for speedy and precise results with high efficiency is anticipated to drive the industry. 3D

Read More...
Choose License Type
Single User - US $2000
Multi User - US $4000
Why Choose Us

24/5 Research support

Get your queries resolved from an industry expert. Request for a free product review before report purchase.

Phone: 1-415-349-0054

Toll Free: 1-888-928-9744

Email: [email protected]

Custom research service

Speak to the report author to design an exclusive study to serve your research needs.

Quality assurance

A testimonial for service excellence represented in the form of BBB "A" Accreditation.

Information security

Your personal and confidential information is safe and secure.

verify